Kestra Medical Technologies, Ltd.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Brian Webster
- Full Time Employees
- 300
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 3933 Lake Washington Blvd NE Kirkland WA United States of America 98033
- IPO Date
- Mar 6, 2025
- CIK
- 0001877184
- Website
- kestramedical.com
- Similar Companies
- Business
- Kestra Medical Technologies, Ltd. (KMTS) develops and commercializes wearable medical devices and digital healthcare solutions focused on protecting patients at risk of sudden cardiac arrest through intuitive, intelligent, and connected diagnostic and therapeutic technologies; its core Cardiac Recovery System platform integrates the ASSURE Wearable Cardioverter Defibrillator (WCD) for continuous monitoring and automatic defibrillation of ventricular arrhythmias, the Kestra CareStation cloud-based remote patient data platform for provider oversight and notifications, the ASSURE patient mobile application for self-management, activity tracking, educational content, and data transmission, and the ASSURE Wearable ECG for post-WCD monitoring using the same SensorFit garment and algorithms. Kestra Medical Technologies operates primarily in the cardiovascular disease segment, targeting heart failure patients and those with low left ventricular ejection fraction awaiting therapy eligibility; it serves healthcare providers including over 550 hospitals across the United States with in-network payer coverage reaching 285 million lives, and maintains a presence in Ireland. Founded in 2014 and headquartered in Kirkland, Washington, the company employs approximately 300 people and has grown its clinical registry beyond 20,000 patients. In July 2024, Kestra Medical Technologies completed an oversubscribed $196 million financing round co-led by Andera Partners, Ally Bridge Group, Longitude Capital, and Omega Funds, with participation from T. Rowe Price Investment Management, Eventide Asset Management, Gilmartin Capital, Bain Capital, and Endeavour Vision, funding commercial expansion of the ASSURE system; in March 2025, it priced an upsized initial public offering on Nasdaq at $17 per share, raising $202 million; fiscal year 2025 delivered record revenue of $59.8 million, up 115% year-over-year, with 3,903 ASSURE prescriptions in Q4 alone (up 43%) and gross margins expanding to 40.5%, alongside commercial team growth to 80 sales territories and FY2026 revenue guidance of $85 million.
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares
Kestra Medical Technologies, Ltd. (KMTS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Kestra Medical Technologies to Present at the BofA Securities 2026 Healthcare Conference
Kestra Showcases Accelerated Innovation at HRS 2026
Kestra Medical Technologies Named a 2026 USA TODAY Top Workplaces Award Winner
The Kestra Director Who Built and Sold a Device Company Keeps Buying Stock
Kestra Medical Technologies Named Finalist for 2026 GeekWire “Deal of the Year”
Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $304,050.00 in Stock
Kestra Medical Technologies, Ltd. (KMTS) Q3 2026 Earnings Call Transcript
Kestra Medical Technologies Reports Third Quarter Fiscal 2026 Financial Results
Kestra Medical Technologies to Report Third Quarter Fiscal 2026 Financial Results on March 17
Kestra Medical Technologies (NASDAQ:KMTS) Insider Brian Daniel Webster Sells 15,000 Shares
Short Interest in Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Rises By 21.5%
KMTS, Biobeat Partner to Expand Diagnostic Insight in Cardiac Recovery
Kestra Medical Technologies, Ltd. (KMTS) Presents at 44th Annual J.P.
Kestra Medical Technologies Announces Strategic Collaboration with Biobeat Technologies to Expand Diagnostic Insight for Wearable Defibrillator Patients During Cardiac Recovery
Kestra Medical Technologies (NASDAQ:KMTS) Stock Price Down 6.1% – Here’s Why
Brian Daniel Webster Sells 15,000 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock
Traci Umberger Sells 10,500 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock
Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Given Consensus Recommendation of “Moderate Buy” by Brokerages